
The waste conversion company is preparing a $125m initial public offering, with backers including Waste Management of Canada seeking a return on their investment.
The Fidelity-backed cancer drug developer has postponed its $191m IPO after setting the range, according to reports.
The computer security firm has raised $128m upon its flotation on NASDAQ, with Intel Capital garnering nearly $12m from the offering.
The internet services company will be floating at between $10 and $12 a share, with Intel Capital among the backers looking to cash in.
FXall, the electronic trading platform formerly known as FX Alliance, which is backed by a range of financial services firms, will offer its shares at between $13.50 and $15.50 when it floats.
The oncological drug developer backed by the firm of SR One's founder outstrips expectations as it raises $55m from its initial public offering, seeing its price rise after the first day of trading.
The agricultural and biomass technology firm is looking to raise $100m when it floats, with shareholders including Monsanto set for a return on their investment.
GlaxoSmithKline-backed ChemoCentryx is looking to raise up to $64m when it floats, hot on the heels of fellow biopharmaceutical company Verastem.
The biotechnology researcher, backed by a GlaxoSmithKline-linked venture capital firm, has set the range for its shares for its initial public offering at between $9 and $11.